ProShare Advisors
CTMX icon

ProShare Advisors’s CytomX Therapeutics CTMX Stock Holding History

ProShare Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,904
Closed -$51K – 1864
2022
Q1 		$51K Sell
18,904
-4,418
-19% -$17K ﹤0.01% 2112
2021
Q4 		$102K Buy
23,322
+1,090
+5% +$6.38K ﹤0.01% 2203
2021
Q3 		$113K Sell
22,232
-6,276
-22% -$33.6K ﹤0.01% 1899
2021
Q2 		$180K Buy
28,508
+3,100
+12% +$24.1K ﹤0.01% 2173
2021
Q1 		$196K Buy
25,408
+8,270
+48% +$65.5K ﹤0.01% 2050
2020
Q4 		$112K Buy
17,138
+4,157
+32% +$29.7K ﹤0.01% 1975
2020
Q3 		$86K Sell
12,981
-494
-4% -$3.66K ﹤0.01% 1538
2020
Q2 		$112K Buy
+13,475
New +$125K ﹤0.01% 1556
2020
Q1 		– Sell
-15,930
Closed -$132K – 1259
2019
Q4 		$132K Sell
15,930
-1,435
-8% -$9.68K ﹤0.01% 1659
2019
Q3 		$128K Sell
17,365
-575
-3% -$5.67K ﹤0.01% 1519
2019
Q2 		$201K Sell
17,940
-2,223
-11% -$23.3K ﹤0.01% 1438
2019
Q1 		$217K Buy
20,163
+220
+1% +$3.25K ﹤0.01% 1426
2018
Q4 		$301K Sell
19,943
-3,840
-16% -$57K ﹤0.01% 1150
2018
Q3 		$440K Buy
23,783
+2,332
+11% +$53.1K ﹤0.01% 1168
2018
Q2 		$490K Sell
21,451
-21
-0.1% -$536 ﹤0.01% 1131
2018
Q1 		$611K Sell
21,472
-3,534
-14% -$101K ﹤0.01% 1026
2017
Q4 		$528K Buy
+25,006
New +$518K ﹤0.01% 1102

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ProShare Advisors's CTMX Position: Q2 2022 in Review

ProShare Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 18,904 shares — an estimated $51K sold.

ProShare Advisors first reported a position in CTMX in Q4 2017 and held it in 17 quarters. The position peaked at $611K in Q1 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • ProShare Advisors reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 18,904 CytomX Therapeutics shares in Q2 2022, an estimated $51K.
  • ProShare Advisors first reported a position in CytomX Therapeutics in Q4 2017 and held it in 17 quarters.
  • ProShare Advisors's CytomX Therapeutics position peaked at $611K in Q1 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.